CLEC3A Promotes Immune Evasion and Tumor Progression by Enhancing PD-L1 Stability to Weaken T Cell Cytotoxicity in Luminal Breast Cancer
CLEC3A promotes BC progression and immune evasion by regulating PD-L1 stability and inhibiting CD8⁺ T cell function. Targeting CLEC3A may enhance anti-tumor immunity and improve patient outcomes in luminal BC.
Authors
- Hongtao Li (ORCID: https://orcid.org/0000-0001-6532-2092)
- Yuan Liu (ORCID: https://orcid.org/0000-0003-2668-0350)
- Xiaojing Zhang (ORCID: https://orcid.org/0000-0002-0595-3500)
- Yanfeng Sun
- Xianming Li (ORCID: https://orcid.org/0000-0002-5099-036X)
- Chen Chen (ORCID: https://orcid.org/0000-0003-0000-5920)
Institutions
- Jinan University (CN)
- ShenZhen People’s Hospital (CN)
- First Affiliated Hospital of Bengbu Medical College (CN)
Publication Details
- Journal
- Breast Cancer Targets and Therapy
- Published
- 2025-10-01
- DOI
- https://doi.org/10.2147/bctt.s533474
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00